.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a mean consequence of 11 months, people along with metastatic gastrointestinal tumors that acquired biomarker-matched therapies based upon circulating lump DNA profiling revealed a higher scientific advantage than those acquiring unrivaled therapy.